Race Oncology (RAC) Stock Price, News & Analysis

Company Overview

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 76,322 shs
• Average Volume: N/A
• Market Capitalization: A$211.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RAC Stock Analysis - Frequently Asked Questions

How were Race Oncology's earnings last quarter?

Race Oncology Limited (ASX:RAC) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) earnings per share for the quarter. Race Oncology had a negative trailing twelve-month return on equity of 71.34% and a negative net margin of 345.18%.

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS), Mount Gibson Iron (MGX), Minotaur Exploration (MEP), Invictus Energy (IVZ), EHang (EH) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Business Services
• Current Symbol: ASX:RAC
• CIK: N/A
• Web: www.raceoncology.com
• Phone: 61 3 9097 1656
• Fax: N/A
• Employees: 12,700
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$13.82 million
• Net Margins: -345.18%
• Pretax Margin: N/A
• Return on Equity: -71.34%
• Return on Assets: -38.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.32
• Quick Ratio: 23.71

Sales & Book Value

• Annual Sales: A$4 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 24.29
• Book Value: A$0.11 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 170,430,000
• Free Float: N/A
• Market Cap: A$211.94 million
• Optionable: Not Optionable
• Beta: 1.74